Common femoral artery antegrade and retrograde approaches have similar access site complications.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
04 2019
Historique:
received: 19 04 2018
accepted: 29 06 2018
pubmed: 12 12 2018
medline: 19 11 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Ipsilateral antegrade access (AA) is an alternative access option for contralateral retrograde access (RA) in treating infrainguinal occlusive disease. Our goal was to assess whether AA is associated with higher access site complications. The Vascular Quality Initiative database was searched from 2010 to 2017 for all infrainguinal peripheral vascular interventions. Cases without access through the common femoral artery or those with multiple accesses were excluded. Access types were classified on the basis of whether the approach was AA or RA. Propensity matching and multivariable analyses were performed to determine the effect of AA on access site complications. There were 45,816 access events identified, 6600 (14.4%) AA and 39,216 (85.6%) RA cases. Patients with AA were older (70.7 vs 69.1 years) and more frequently male (66.5% vs 59.1%), white (79.4% vs 74.6%), and on Medicare (58.4% vs 56%); they were more likely to have end-stage renal disease (12.1% vs 11%), and they were less frequently obese (29.3% vs 36.1%) and less likely to be currently smoking (25.5% vs 28.7%), to be diabetic (56% vs 59.8%), to have chronic obstructive pulmonary disease (20.7% vs 21.8%), and to ambulate independently (69.8% vs 72.5%; P < .05 for all). Patients with AA were more likely to have a history of a prior percutaneous vascular intervention (9.3% vs 7%), inflow bypass (6.2% vs 1.8%), and leg bypass (12.6% vs 8.9%; P < .001 for all). The AA technique was more frequently used in the setting of tissue loss (51.8% vs 45.1%) and for tibial intervention (46.3% vs 35.3%; P < .001 for both). There were no significant differences between AA and RA in overall hematoma (3% vs 2.7%; P = .21) or hematoma requiring intervention (0.4% vs 0.4%; P = .75) rates. There was no significant difference in access site occlusion or stenosis between AA and RA (0.2% vs 0.3%; P = .68). These findings were confirmed with 2:1 matching based on preoperative data and type of intervention. Multivariable analysis demonstrated that AA is not associated with increased risk of any hematoma (odds ratio [OR], 1.15; 95% confidence interval [CI], 0.98-1.35; P = .082) or hematoma requiring intervention (OR, 0.88; 95% CI, 0.57-1.35; P = .56). Multivariable analysis of the matched data confirmed these findings between AA and RA for hematoma (OR, 0.88; 95% CI, 0.73-1.06; P = .17) and hematoma requiring intervention (OR, 1.17; 95% CI, 0.7-1.95; P = .55). AA is safe, and it was not found to be associated with increased access site complications, such as hematoma, in the large Vascular Quality Initiative sample. This approach remains a viable alternative to traditional RA.

Identifiants

pubmed: 30527937
pii: S0741-5214(18)32219-5
doi: 10.1016/j.jvs.2018.06.226
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1160-1166.e2

Informations de copyright

Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Jeffrey J Siracuse (JJ)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass. Electronic address: jeffrey.siracuse@bmc.or.

Alik Farber (A)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Thomas W Cheng (TW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Stephen J Raulli (SJ)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Douglas W Jones (DW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Jeffrey A Kalish (JA)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Matthew R Smeds (MR)

Division of Vascular and Endovascular Surgery, St. Louis University, St. Louis, Mo.

Denis Rybin (D)

School of Public Health, Boston University, Boston, Mass.

Marc L Schermerhorn (ML)

Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH